| FTV |
Report |
Core Organic Growth (Q2 2026) |
BEAT |
pred ~4.5% vs. cons 3.76% |
MEDIUM |
| FTV |
Report |
AHS Revenue (Q2 2026) |
BEAT |
pred ~$340M vs. cons $333M |
MEDIUM |
| FTV |
Report |
Adj. EPS (Q2 2026) |
BEAT |
pred ~$0.72 vs. cons $0.708 |
MEDIUM |
| FTV |
Guide |
FY 2026 Adj. EPS (FY 2026) |
BETTER |
guide ~$3.05 midpoint vs. cons $2.999 |
MEDIUM |
| FTV |
Guide |
FY 2026 Core Growth (FY 2026) |
BETTER |
guide ~3%-4% midpoint vs. cons 3.03% |
MEDIUM |
| FTV |
Guide |
Q3 2026 EPS qualitative (Q3 2026) |
LOWER |
guide ~$0.72-$0.74 vs. implied cons ~$0.75 |
MEDIUM |
| FTV |
Return |
Day-1 residual (stock − beta × S&P 500) |
+2.5% |
— |
MEDIUM |
| FTV |
Return |
5-day cumulative residual |
+2.5% (STABILIZE) |
STABILIZE — Archetype A history shows front-loaded move; modest estimate revisions (+1-2% FY EPS) provide slight follow-through but no meaningful fade or acceleration |
MEDIUM |